The 2013 American college of cardiology/American heart association guidelines on treating blood cholesterol and assessing cardiovascular risk: A busy practitioner's guide

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 4, 2014, Pages 869-892

  Gupta, Arpeta ^a   Smith, Donald A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

2013 ACC AHA cholesterol guidelines; Blood cholesterol guideline; Cardiovascular risk guideline; Pooled cohort equations; Primary prevention of ASCVD; Statin therapy; Ten year ASCVD risk

Indexed keywords

ATORVASTATIN; CHOLESTEROL; DRUG ADMINISTRATION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD; CARDIOVASCULAR DISEASES; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG THERAPY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER FAILURE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; META ANALYSIS; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE RIGIDITY; MYALGIA; PATIENT DECISION MAKING; PRACTICE GUIDELINE; PREVENTION; PRIMARY PREVENTION; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; STABLE ANGINA PECTORIS; STANDARDS; UNITED STATES;

ADMINISTRATION AND DOSAGE; AMERICAN HEART ASSOCIATION; BLOOD; CARDIOVASCULAR DISEASES; DRUG THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREVENTION AND CONTROL; RISK ASSESSMENT; SOCIETIES, MEDICAL; STANDARDS; UNITED STATES;

EID: 84964296314     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2014.08.006     Document Type: Review

References (47)

1. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129(3):399-410. http://dx.doi.org/10.1161/01.cir.0000442015. 53336.12.
2. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the united states, 1990-2010. N Engl J Med 2014;370(16):1514-23. http://dx.doi.org/ 10.1056/NEJMoa1310799.
3. Kaufman HW, Blatt AJ, Huang X, et al. Blood cholesterol trends 2001-2011 in the United States: analysis of 105 million patient records. PLoS One 2013;8(5): e63416. http://dx.doi.org/10.1371/journal.pone.0063416.
4. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B): 2889-934. http://dx.doi.org/10.1016/j.jacc.2013.11.002.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med 2014;160(5):339-43. http://dx.doi.org/10.7326/M14-0126.
6. Pencina MJ, Navar-Boggan AM, D'Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370(15): 1422-31. http://dx.doi.org/10.1056/NEJMoa1315665.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.
8. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 2004;44(3):720-32.http://eresources.library.mssm. edu:2213/10.1016/j.jacc.2004.07.001.
9. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117(6): 743-53. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.699579.
10. Lackland DT, Elkind MS, D'Agostino RS, et al. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43(7): 1998-2027. http://dx.doi.org/10.1161/STR.0b013e31825bcdac.
11. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2935-59. http://dx.doi.org/10.1016/j.jacc.2013. 11.005.
12. Fried LP, Borhani NO, Enright P, et al. The cardiovascular health study: design and rationale. Ann Epidemiol 1991;1(3):263-76.
13. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41(11):1105-16. pii:0895-4356(88)90080-7.
14. Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 2003; 56(9):880-90. pii:S0895435603000556.
15. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113(6):791-8. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.548206.
16. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013;382(9907):1762-5. http://dx.doi.org/10.1016/ S0140-6736(13)62388-0.
17. Muntner P, Safford MM, Cushman M, et al. Comment on the reports of overestimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation 2014;129(2):266-7. http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007648.
18. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA 2014;311(14): 1406-15. http://dx.doi.org/10.1001/jama.2014.2630.
19. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 2003;163(16): 1966-72. http://dx.doi.org/10.1001/archinte.163.16.1966.
20. Marma AK, Berry JD, Ning H, et al. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes 2010;3(1):8-14. http://dx.doi.org/10.1161/CIRCOUTCOMES.109.869727.
21. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004;94(1): 20-4. http://dx.doi.org/10.1016/j.amjcard.2004.03.023.
22. Pencina MJ, D'Agostino RB, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 2009;119(24): 3078-84. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.816694.
23. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366(4):321-9. http://dx.doi.org/10.1056/NEJMoa1012848.
24. McClelland RL, Chung H, Detrano R, et al. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-ethnic Study of Atherosclerosis (MESA). Circulation 2006;113(1):30-7. pii:CIRCULATIONAHA.105.580696.
25. Peters SA, den Ruijter HM, Bots ML, et al. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 2012;98(3):177-84. http://dx.doi.org/10.1136/heartjnl-2011-300747.
26. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012;308(8):796-803. http://dx.doi.org/10.1001/jama.2012.9630.
27. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81. http://dx.doi.org/10.1016/S0140-6736(10)61350-5.
28. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14. http://dx.doi.org/10.1007/s10557-005-5686-z.
29. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013;166(3):597-603. http://dx.doi.org/10.1016/j.ahj.2013.06.004.
30. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107(19):2409-15. http:// dx.doi.org/10.1161/01.CIR.0000068312.21969.C8.
31. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375(9716): 735-42. http://dx.doi.org/10.1016/S0140-6736(09)61965-6.
32. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172(2):144-52. http://dx.doi.org/10.1001/archinternmed.2011.625.
33. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305(24):2556-64. http://dx.doi.org/10.1001/jama.2011.860.
34. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380(9841):565-71. http://dx.doi.org/10.1016/S0140-6736(12) 61190-8.
35. Maki KC, Ridker PM, Brown WV, et al. An assessment by the statin diabetes safety task force: 2014 update. J Clin Lipidol 2014;8(Suppl 3):S17-29. http:// dx.doi.org/10.1016/j.jacl.2014.02.012.
36. Zhou Y, Yuan Y, Cai RR, et al. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opin Pharmacother 2013;14(12):1575-84. http:// dx.doi.org/10.1517/14656566.2013.810210.
37. Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin Proc 2013;88(11):1213-21. http://dx.doi.org/10.1016/j.mayocp.2013.07.013.
38. Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med 2013;159(10):688-97. http://dx.doi.org/10. 7326/0003-4819-159-10-201311190-00007.
39. Jacobson TA. NLA task force on statin safety-2014 update. J Clin Lipidol 2014; 8(Suppl 3):S1-4. http://dx.doi.org/10.1016/j.jacl.2014.03.003.
40. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934): 1383-9.
41. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22. pii:S0140-6736(02) 09327-3.
42. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35. pii:NEJMoa050461.
43. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58. pii:S0140-6736(03)12948-0.
44. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96. http://dx.doi.org/10.1016/S0140-6736(04) 16895-5.
45. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207. http://dx.doi.org/10.1056/NEJMoa0807646.
46. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci 1963;107:539-56.
47. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979; 110(3):281-90.